An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial (Q34593792)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial |
scientific article |
Statements
1 reference
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial (English)
1 reference
Bernard Escudier
1 reference
Christopher Wood
1 reference
Pramod Srivastava
1 reference
Ronald Bukowski
1 reference
Louis Lacombe
1 reference
Andrei I Gorelov
1 reference
Sergei Gorelov
1 reference
Peter Mulders
1 reference
Henryk Zielinski
1 reference
Axel Hoos
1 reference
Florentina Teofilovici
1 reference
Leah Isakov
1 reference
Robert Flanigan
1 reference
Robert Figlin
1 reference
Renu Gupta
1 reference
C-100-12 RCC Study Group
1 reference
Identifiers
1 reference